Year 2021 / Volume 28 / Supplement 1

Article Osteoarthritis Monographic

Intra-articular botulinum toxin and ozone in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 73-79 / DOI: 10.20986/resed.2021.3857/2020

Daniel Samper


ABSTRACT

Osteoarthritis pain continues to be one of the main causes of medical visit due to the insufficient efficacy of established treatments, therefore, the need arises to search for new therapies that improve the analgesic response.
Intra-articular injection of botulinum toxin and/or medicinal ozone are two of the new options to consider in this pathology.
We develop in this chapter a review of the management of these two analgesic options.



RESUMEN

El dolor por osteoartrosis continúa siendo una de las principales causas de consulta médica debido a la insuficiente eficacia de los tratamientos establecidos, y por ello surge la necesidad de buscar nuevas terapias que mejoren la respuesta analgésica.
La inyección intrarticular de toxina botulínica y/o de ozono medicinal son dos de las nuevas opciones a considerar en esta patología.
Realizamos en este capítulo una revisión del manejo de estas dos opciones analgésicas.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis. 2014;209(2):183-91. DOI: 10.1093/infdis/jit449.
2. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-musuclar junction. J Psysiol (Lond) 1949;109(1-2):10-24. DOI: 10.1113/jphysiol.1949.sp004364.
3. Scott AB. Botulisnum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pedaitr Ophtalmol Strabismus. 1980;17(1):21-5.
4. Safarpur Y, Jabbari B. Botulinum toxin treatment of movement disorders. Curr Treat Options Neurol. 2018;20(2):4. DOI: 10.1007/s11940-018-0488-3.
5. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis. JAMA. 2012;307(16):1736-45. DOI: 10.1001/jama.2012.505.
6. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6(6):CD011616. DOI: 10.1002/14651858.CD011616.pub2.
7. Montecucco C, Molgo J. Botulinal neurotoxins: Revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274-9. DOI: 10.1016/j.coph.2004.12.006.
8. Mahowald ML, Singh JA,Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006;9(2-3):179-88. DOI: 10.1007/BF03033937.
9. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59(1):65-9. DOI: 10.1016/0304-3959(94)90048-5.
10. Gobel H. Botulinum toxin A in pain management: mechanisms of action and rationales for optimum use. Pain Headache. 2003;14:4-22.
11. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38(2):245-58. DOI: 10.1016/s0041-0101(99)00153-1.
12. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache. 2004;44(1):35-42, discussion 42-43. DOI: 10.1111/j.1526-4610.2004.04007.x.
13. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(Pt 16):2864-74. DOI: 10.1242/jcs.012211.
14. Cheng J, Liu W, Duffney LJ, Yan Z. SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors. J. Physiol. 2013;591(16):3935-47. DOI: 10.1113/jphysiol.2013.255075.
15. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem. 2004;279(24):25665-72. DOI: 10.1074/jbc.M311515200.
16. Mahowald ML, Singh JA, Goelz E, Kushnaryov A, Krug HE. Intra-articular botulinum toxin type A: A new approach to treat arthritis joint pain. In: American College of Rheumatology Annual meeting; 2007. p. Abs 1688.
17. Singh JA, Mahowald ML, Noorbaloochi S. Intra-arti- cular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009;153(5):205-16. DOI: 10.1016/j.trsl.2009.02.004.
18. Dykstra DD, Stuckey MW, Schimpff SN, Singh JA, Mahowald ML. Use of botulinum toxins for chronic headaches: a focused review. Pain Clin. 2007;19:27-32.
19. Fenollosa P, Izquierdo RM, Canós MA, Pallarés J. Efectos de la toxina botulínica A (Botox) intraarticular en la artrosis de rodilla avanzada. Rev Soc Esp Dolor. 2011;18(6):320-5.
20. Bahman J, Machado D. Treatment of refractory pain with botulinum toxins-An evidence -based review. Pain Medicine 2011;12(11):1594-606. DOI: 10.1111/j.1526-4637.2011.01245.x.
21. Wong SM, Hui Ac, Tong PY. Treatment of lateral epicondylitis with botulinum toxin: A randomized, double blind, placebo-controlled trial. Ann Intern Med. 2005;143(11):793-7. DOI: 10.7326/0003-4819-143-11-200512060-00007.
22. Hayton MJ, Santini AJ, Hughes PJ, Frostick SP, Trail IA, Stanley JK. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am. 2005;87(3):503-7. DOI: 10.2106/JBJS.D.01896.
23. Placzek R, Drescher W, Deuretzbacher G, Hempfing A, Meiss AL. Tretament of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am. 2007;89(2):255-60. DOI: 10.2106/JBJS.F.00401.
24. Espandar R, Heidari P, Rasouli MR, Saadat S, Farzan M, Rostami M, et al. Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: A randomized controlled trial. CMAJ. 2010;182(8):768-73. DOI: 10.1503/cmaj.090906.
25. Singh J, Mahowald M, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009;153(5):205-16. DOI: 10.1016/j.trsl.2009.02.004.
26. Joo YJ, Yoon SJ, Kim CW, Lee JH, Kim YJ, Koo JH, et al. A comparison of the short-term effects of a botulinum toxin type A and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013;37(2):208-14. DOI: 10.5535/arm.2013.37.2.208.
27. Durán-Hernández S, Soto-Rodríguez JF, Allen-Bobadilla J, Durán Hernández N, García-Mosco P. Tratamiento conservador de la osteoartrosis de cadera con toxina botulínica tipo A. Gac Med Mex. 2019;155(Suppl 1):S56-S61. DOI: 10.24875/GMM.19005151.
28. Bonn A, Smith J, Dahm D, Sorenson E, Larson D, Fitz-Gibbon P, et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R 2010;3(4):268-76. DOI: 10.1016/j.pmrj.2010.02.011.
29. Hsieh L, Wu Ch. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PMR 2016;8(12):1127-35. DOI: 10.1016/j.pmrj.2016.05.009.
30. McAlindon TE, Schmidt U, Bugarin D, Abrams S, Geib T, DeGryse RE, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double blind study. Osteoarthritis Cartilage. 2018(26):1291-9. DOI: 10.1016/j.joca.2018.05.001.
31. Shukla D, Sreedhar S, Rastogi V. A comparative study of botulinum toxin: A con triamcinolone compared to triamcinolone alone in the treatment of osteoarthritis of knee. Anesth Essays Res. 2018;12(1):47-9. DOI: 10.4103/aer.AER_210_17.
32. Bao X, Tan J, Flyzik M, Ma X, Liu H, Liu H. Effect of therapeutic exercice on knee osteoarthritis after intra-articular injection of botulinum toxin type A, hyaluronidate or saline: a randomized controlled trial. J Rehabil Med. 2018;50(6):534-41. DOI: 10.2340/16501977-2340.
33. Mendes JG, Natour J, Nunes-Tamashiro JC, Toffolo SR, Rosenfeld A, Furtado RNV. Comparison between intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: a randomized controlled trial. Clinical Rehabilitation. 2019;33(6):1015-1026. DOI: 10.1177/0269215519827996.
34. Wu T, Song H, Dong Y, Ye Y, Li J. Intra-articular injections of botulinum toxin a for refractory joint pain: a systematic review and meta-analysis. Clin Rehabil. 2017;31(4):435-43. DOI: 10.1177/0269215516644951.
35. Courseau M, Vergne P, Ranoux D, Lachatre A. Efficacy of intra-articular botulinum toxin in osteoarticular joint pain: a meta-analysis of randomized controlled trials. Clin J Pain. 2018;34(4):383-9. DOI: 10.1097/AJP.0000000000000538.
36. Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes- an evidence based review. Toxicon 2018;147:120-8. DOI: 10.1016/j.toxicon.2018.01.017.
37. Zhai S, Huang B, Yu K. The efficacy and safety of botulinum toxin type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019;48(4):300060519895868. DOI: 10.1177/0300060519895868.
38. Kolasinski S, Neogi T, Hochberg M, Oatis C, Guyatt G, Block J, et al. 2019 American College of Reumathology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip and knee. Arthritis Care Res. 2020;72(2): 149-62. DOI: 10.1002/acr.24131.
39. Bocci V. General mechanisms of action of ozone therapy and mechanisms in pain treatment. Rev Soc Esp Dolor. 2005;12(Supl. II):24-36.
40. Hidalgo-Tallón FJ, Torres LM. Ozonoterapia en medicina del dolor. Revisión. Rev Soc Esp Dolor. 2013;20(6):291-300.
41. Bocci V, Corradeschi F. Studies on the biological effects of ozone: III and attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res 1993;12(2):121-6.
42. Bocci V. Mecanismos de acción generales de la ozonoterapia y mecanismos en el tratamiento del dolor. Rev Soc Esp Dolor. 2005;12(Supl. II):24-36.
43. Viebahn-Haensler R. Milestones of medical ozone. Rev Soc Esp Dolor. 2005;12(Supl. II):3-9.
44. De Lucas JC. Peripheral infiltrations with ozone. Indications, techniques and clinical experience. Rev Soc Esp Dolor. 2005;12(Supl. II):37-47.
45. Seyam O, Smith N, Reid I, Gandhi J, Jiang W, Ali S. Clinical utility of ozone therapy for musculoskeletal disorders. Med Gas Res. 2018;8(3):103-10. DOI: 10.4103/2045-9912.241075.
46. Al-Jaziri A, Mahmoodi S. Painkilling effect of ozone-oxygen injection on spine and joint osteoarthritis. Saudi Med J. 2008;29(4):553-7.
47. Li JH, Zhou LX, Li GY, Cheng B. Treatment of middle-aged and aged patients with knee osteoarthritis of yang-deficiency induced cold-damp syndrome by ozone combined Chinese materia medica: a clinical research Chin J Int Trad West Med. 2013;33(4):471-5.
48. Samper D, Rovira G, Monerris M, González M, Mazo V. Tratamiento de la gonalgia por gonartrosis con ozono intrarticular. Rev Soc Esp Dolor. 2013;20(3):107-12.
49. Babaei-Ghazani A, Najarzadeh S, Mansoori K, Forough B, Pezhman S, Ebadi S, et al. The effects of ultrasound-guided corticosteroid injection compared to oxygen-ozone (O2-O3) injection in patients with knee osteoarthritis: a randomized controlled trial. Clinical Reumatology. 2018;37:2517-27.
50. Feng X, Beiping L. Therapeutic efficacy of ozone injection into the knee for the osteoarthritis patient along with oral celecoxib and glucosamine. J Clin Diagn Res. 2017;11(9):UC01-UC03. DOI: 10.7860/JCDR/2017/26065.10533.
51. Lopes de Jesus C, dos Santos F, Oliveira L, Monteiro I, Sousa M, Fernandes V. Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study. PLoS ONE. 2017;12(7):e0179185. DOI: 10.1371/journal.pone.0179185.
52. Mutlu T, Mutlu S, Dernek B, Komur B, Aydogmus S, Nur F. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. Knee Surg Traumatol Arthrosc. 2017;25(2):485-92. DOI: 10.1007/s00167-016-4110-5.
53. Fernández-Cuadros M, Pérez-Moro O, Albajadejo-Florin MJ, Álava-Rabasa S. El ozono intrarticular modula la inflamación, mejora el dolor, la rigidez, la función y tiene un efecto anabólico sobre la artrosis de rodilla: estudio cuasiexperimental prospectivo tipo antes-después, 115 pacientes. Rev Soc Esp. Dolor 2020;27(2):78-88.
54. Ukusoy G, Bilge A, Öztürk Ö. Comparison of corticosteroid injection and ozone injection for relief of pain in chronic lateral epicondylitis. Acta Orthop Belg. 2019;85(3):317-24.
55. Hedayatabad J, Kachooei A, Chaharjouy N, Varizi N, Mehrad-Majd H, Emadzadeh M, et al. The effect of ozone (O3) versus hyaluronic acid on pain and function in patients with knee osteoarthritis: A Systematic review and meta-analysis. Arch Bone Jt Surg. 2020;8(3):343-54. DOI: 10.22038/abjs.2020.46925.2292.
56. Noori-Zadeh A, Bakhtiyari S, Khooz R, Haghani K, Darabi S. Intra-articular ozone therapy efficiently attenuates pain in knee osteoarthritic subjects: A systematic review and meta-analysis. Complement Ther Med. 2019;42:240-7. DOI: 10.1016/j.ctim.2018.11.023.
57. Souza C, Respizzi S, Virelli L, Vandenbulcke F, iacono F, Kon E, et al. Oxygen-Ozone therapy for the treatment of knee osteoarthritis: A systematic review of randomized controlled trials. Arthroscopy. 2020;36(1):277-86. DOI: 10.1016/j.arthro.2019.05.043.
58. Palanca I, Puig MM, Elola J, Bernal JL, Paniagua JL, Grupo de Expertos. Unidad de tratamiento de dolor: estándares y recomendaciones. Madrid: Ministerio de Sanidad, Política Social e Igualdad; 2011.

Artículos relacionados

A case of neuralgic amyotrophy after vaccination against COVID-19

Rev. Soc. Esp. Dolor. 2023; 30(3): 187-190 / DOI: 10.20986/resed.2023.4021/2022

Ultrasound-guided ankle nerve block as adjuvant therapy in chronic pain after occupational injury.

Rev. Soc. Esp. Dolor. 2023; 30(3): 178-186 / DOI: 10.20986/resed.2023.4035/2022

Effect of therapeutic exercise in persons with sacroiliac joint dysfunction: a systematic review and meta-analysis

Rev. Soc. Esp. Dolor. 2023; 30(2): 95-108 / DOI: 10.20986/resed.2023.4034/2022

Pulsed radiofrequency of the supraescapular nerve in the treatment of painful shoulder

Rev. Soc. Esp. Dolor. 2023; 30(1): 36-48 / DOI: 10.20986/resed.2023.4046/2022

Effectiveness of cluneal nerve block for the treatment of chronic low back pain

Rev. Soc. Esp. Dolor. 2023; 30(1): 30-35 / DOI: 10.20986/resed.2023.4023/2022

Treatment of painful scars with 5 % lidocaine patch: clinical cases report

Rev. Soc. Esp. Dolor. 2022; 29(3): 187-191 / DOI: 10.20986/resed.2022.3997/2022

Usefulness of percutaneous basivertebral nerve thermorizotomy for the treatment of chronic low back pain. Literature review

Rev. Soc. Esp. Dolor. 2022; 29(3): 169-174 / DOI: 10.20986/resed.2022.4044/2022

Efficacy of physiotherapy on the anxiety and depression in patients with chronic pain: a systematic review

Rev. Soc. Esp. Dolor. 2022; 29(3): 157-168 / DOI: 10.20986/resed.2022.3994/2022

Peripheral facial palsy following glossopharyngeal block: a case report

Rev. Soc. Esp. Dolor. 2022; 29(2): 114-118 / DOI: 10.20986/resed.2022.3963/2021

The biopsychosocial nature of chronic pelvic floor pain: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 97-113 / DOI: 10.20986/resed.2022.3981/2022

Myofascial pain syndrome in the female pelvic floor musculature. Narrative review of the literature

Rev. Soc. Esp. Dolor. 2022; 29(2): 88-96 / DOI: 10.20986/resed.2022.3970/2022

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Medical cannabis treatment in patients with visceral chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 32-42 / DOI: 10.20986/resed.2022.4030/2022

Is medical cannabis useful for the treatment of fibromyalgia?

Rev. Soc. Esp. Dolor. 2022; 29(13): 27-31 / DOI: 10.20986/resed.2022.4029/2022

Medical cannabis and cancer: benefits for cancer pain and other related symptoms

Rev. Soc. Esp. Dolor. 2022; 29(13): 14-19 / DOI: 10.20986/resed.2022.4026/2022

Current evidence of medical cannabis treatment in patients with chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 10-13 / DOI: 10.20986/resed.2022.4024/2022

Some preclinical results of cannabinoids and pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 3-9 / DOI: 10.20986/resed.2022.4033/2022

Treatment alternatives for anemia in terminally ill patients diagnosed with oncology

Rev. Soc. Esp. Dolor. 2022; 29(1): 56-56 / DOI: 10.20986/resed.2022.3992/2022

Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

Rev. Soc. Esp. Dolor. 2022; 29(1): 51-55 / DOI: 10.20986/resed.2021.3930/2021

Complex regional pain syndrome, rehabilitation, pharmacotherapy, psychology.

Rev. Soc. Esp. Dolor. 2022; 29(1): 34-50 / DOI: 10.20986/resed.2022.3978/2022

Use of 8 % capsaicin patches for the treatment of lumbar neuropathic pain

Rev. Soc. Esp. Dolor. 2022; 29(1): 28-33 / DOI: 10.20986/resed.2022.3995/2022

Peroneal neuropathy caused by an extraneural ganglion: literary review and treatment proposal. A non-positive case

Rev. Soc. Esp. Dolor. 2021; 28(6): 354-357 / DOI: 10.20986/resed.2022.3919/2021

Retrolaminar ultrasound guided block as analgesic treatment for post herpetic neuralgia: case report

Rev. Soc. Esp. Dolor. 2021; 28(6): 350-353 / DOI: 10.20986/resed.2022.3920/2021

Use of botulinum toxin for pain after amputation

Rev. Soc. Esp. Dolor. 2021; 28(6): 332-342 / DOI: 10.20986/resed.2022.3943/2021

Lumbar epidural steroids injections reduce catastrophism on the lumbosacral radicular syndrome

Rev. Soc. Esp. Dolor. 2021; 28(6): 325-331 / DOI: 10.20986/resed.2022.3947/2021

End-of-life transfusions in patients with an oncological diagnosis

Rev. Soc. Esp. Dolor. 2021; 28(6): 319-324 / DOI: 10.20986/resed.2022.3956/2021

Botulinum toxin: pluripotent analgesic effect

Rev. Soc. Esp. Dolor. 2021; 28(6): 305-306 / DOI: 10.20986/resed.2022.3982/2022

Late onset of restless legs syndrome as a methadone withdrawal symptom in cancer patients: report of two cases

Rev. Soc. Esp. Dolor. 2021; 28(5): 298-300 / DOI: 10.20986/resed.2021.3889/2021

Thalalgic triad. A new clinical entity from a case series

Rev. Soc. Esp. Dolor. 2021; 28(5): 276-281 / DOI: 10.20986/resed.2021.3941/2021

Efficacy and complications of analgesic techniques for the treatment of moderate to severe postoperative acute pain

Rev. Soc. Esp. Dolor. 2021; 28(5): 264-265 / DOI: 10.20986/resed.2021.3942/2021

Capsaicin: a treatment to pick the mouth

Rev. Soc. Esp. Dolor. 2021; 28(5): 252-253 / DOI: 10.20986/resed.2021.3961/2021

Brachial plexus schwannoma and botulinum toxin: a case report

Rev. Soc. Esp. Dolor. 2021; 28(4): 242-245 / DOI: 10.20986/resed.2021.3924/2021

Pharmacological osteonecrosis in maxillofacial surgery, period 2013-2019

Rev. Soc. Esp. Dolor. 2021; 28(4): 211-218 / DOI: 10.20986/resed.2021.3837/2020

Clinical recommendations for rehabilitation of people with fibromyalgia. A narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 194-210 / DOI: 10.20986/resed.2021.3932/2021

The multifaceted reality of adherence to analgesic treatment

Rev. Soc. Esp. Dolor. 2021; 28(4): 175-176 / DOI: 10.20986/resed.2021.3945/2021

Persistent hiccups after epidural injection of betamethasone: a case report

Rev. Soc. Esp. Dolor. 2021; 28(2): 169-171 / DOI: 10.20986/resed.2021.3914/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Botulinum toxin for the treatment of myofascial pain syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 100-110 / DOI: 10.20986/resed.2021.3902/2021

Evolution of low back pain in cancer patients treated with interventional pain management

Rev. Soc. Esp. Dolor. 2021; 28(2): 76-81 / DOI: 10.20986/resed.2021.3901/2021

Analgesic effectiveness of tapentadol in neuropathic pain secondary to post-laminectomy syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 71-75 / DOI: 10.20986/resed.2021.3822/2020

Transfusions at the end of life. Review of some important considerations

Rev. Soc. Esp. Dolor. 2021; 28(1): 47-52 / DOI: 10.20986/resed.2021.3831/2020

Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

Rev. Soc. Esp. Dolor. 2021; 28(1): 19-26 / DOI: 10.20986/resed.2021.3824/2020

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

Platelet rich plasma and intra-articular mesenchymal stem cells in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 80-84 / DOI: 10.20986/resed.2021.3858/2020

Infiltrations of steroids and hyaluronic acid in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 64-72 / DOI: 10.20986/resed.2021.3854/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

News in the clinical practice guidelines regarding the treatment of the hip, knee and hands osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 38-42 / DOI: 10.20986/resed.2021.3870/2020

Experimental models for pain evaluation in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 18-30 / DOI: 10.20986/resed.2021.3872/2020

Ethiopathogenic mechanism of osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 11-17 / DOI: 10.20986/resed.2021.3851/2020

Epidemiology, clinical impact and therapeutic objectives in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 4-10 / DOI: 10.20986/resed.2021.3874/2020

Transitional pain clinic

Rev. Soc. Esp. Dolor. 2020; 27(6): 369-374 / DOI: 10.20986/resed.2020.3840/2020

Study of pain in rehabilitation treatments

Rev. Soc. Esp. Dolor. 2020; 27(6): 361-368 / DOI: 10.20986/resed.2020.3809/2020

Impact of group psychological intervention on conventional radiofrequency tributary patients

Rev. Soc. Esp. Dolor. 2020; 27(6): 349-360 / DOI: 10.20986/resed.2020.3830/2020

A 14-month physiotherapy follow up to a child with Sandifer syndrome

Rev. Soc. Esp. Dolor. 2020; 27(5): 329-331 / DOI: 10.20986/resed.2020.3816/2020

School of non-oncologic chronic pain patients and opioid treatment

Rev. Soc. Esp. Dolor. 2020; 27(5): 324-328 / DOI: 10.20986/resed.2020.3804/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Identification of signs and symptoms for the diagnosis of discogenic low back pain: mapping review

Rev. Soc. Esp. Dolor. 2020; 27(5): 292-297 / DOI: 10.20986/resed.2020.3803/2020

Efficacy of lidocaine perfusions in fibromyalgia: a prospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 287-291 / DOI: 10.20986/resed.2020.3796/2020

Back to the future in the treatment of postoperative acute pain

Rev. Soc. Esp. Dolor. 2020; 27(5): 285-286 / DOI: 10.20986/resed.2020.3850/2020

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Clinical pathophysiology in patients with sickle cell disease: the transition from acute to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 257-268 / DOI: 10.20986/resed.2020.3814/2020

Gender determinants in the approach to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 252-256 / DOI: 10.20986/resed.2020.3802/2020

Sociodemographic and clinical characterization in patients with chronic back pain, Cienfuegos 2019

Rev. Soc. Esp. Dolor. 2020; 27(4): 239-245 / DOI: 10.20986/resed.2020.3798/2020

Spinal cord stimulation. Analysis of the diagnostic indications

Rev. Soc. Esp. Dolor. 2020; 27(4): 234-238 / DOI: 10.20986/resed.2020.3777/2019

Suboccipital decompression as an alternative in the treatment of pain secundary to occipital neuralgia: a case series

Rev. Soc. Esp. Dolor. 2020; 27(3): 221-226 / DOI: 10.20986/resed.2020.3791/2020

Symptomatic treatment for migraña. Drugs used and related variables. Results of the european survey on work and migraine

Rev. Soc. Esp. Dolor. 2020; 27(3): 178-191 / DOI: 10.20986/resed.2020.3744/2019

Drug consumption used for musculoskeletal pain treatment in a cohort of blue-collar workers in Zaragoza (Spain)

Rev. Soc. Esp. Dolor. 2020; 27(3): 150-159 / DOI: 10.20986/resed.2020.3749/2019

Clinical experience with the implementation of a postdural puncture headache multidisciplinary protocol

Rev. Soc. Esp. Dolor. 2020; 27(2): 133-137 / DOI: 10.20986/resed.2020.3782/2019

Management of breakthrough pain associated with the cure of skin ulcers

Rev. Soc. Esp. Dolor. 2020; 27(2): 113-126 / DOI: 10.20986/resed.2020.3755/2019

The ozone paradigm in pain treatment

Rev. Soc. Esp. Dolor. 2020; 27(2): 69-71 / DOI: 10.20986/resed.2020.3807/2020

Conventional radiofrequency for genicular nerves in treatment of knee osteoarthritis

Rev. Soc. Esp. Dolor. 2020; 27(1): 59-60 / DOI: 10.20986/resed.2016.3515/2016

Review of the impact of acupuncture treatment on the management of nonspecific low back pain

Rev. Soc. Esp. Dolor. 2020; 27(1): 53-58 / DOI: 10.20986/resed.2020.3762/2019

Effectiveness of the association of lacosamide in trigeminal neuralgia

Rev. Soc. Esp. Dolor. 2020; 27(1): 50-52 / DOI: 10.20986/resed.2019.3738/2019

Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review

Rev. Soc. Esp. Dolor. 2020; 27(1): 37-49 / DOI: 10.20986/resed.2020.3717/2018

Efficacy of pregabalin, gabapentin and duloxetine in neuropathic pain verified by the p-curve analysis

Rev. Soc. Esp. Dolor. 2020; 27(1): 16-23 / DOI: 10.20986/resed.2020.3727/2019

News in the treatment of back pain: are the future cell therapies?

Rev. Soc. Esp. Dolor. 2020; 27(1): 3-4 / DOI: 10.20986/resed.2020.3792/2020

Abducens nerve palsy associated with dural puncture and neurovascular compression

Rev. Soc. Esp. Dolor. 2019; 26(6): 376-378 / DOI: 10.20986/resed.2019.3722/2018

Intratecal baclophene for the treatment of pain and spasticity in stiff man syndrome: a case report

Rev. Soc. Esp. Dolor. 2019; 26(6): 368-371 / DOI: 10.20986/resed.2019.3745/2019

Neurolytic procedures for pancreatic cáncer pain: a systematic review and a proposal for an algorithm treatment

Rev. Soc. Esp. Dolor. 2019; 26(6): 342-358 / DOI: 10.20986/resed.2019.3715/2018

Pyoderma gangrenosum, undocumented complication of a spinal cord stimulation

Rev. Soc. Esp. Dolor. 2019; 26(5): 309-312 / DOI: 10.20986/resed.2019.3725/2019

NMDA antagonism in the treatment of cluster headache

Rev. Soc. Esp. Dolor. 2019; 26(4): 247-250 / DOI: 10.20986/resed.2019.3710/2018

Characterization of pain in patients with breast cancer attending the Oncology Unit of the San José Hospital

Rev. Soc. Esp. Dolor. 2019; 26(4): 221-226 / DOI: 10.20986/resed.2019.3692/2018

Information and communication technologies applied among medical professionals who perform pain treatment

Rev. Soc. Esp. Dolor. 2019; 26(3): 175-183 / DOI: 10.20986/resed.2019.3709/2018

Sublingual fentanyl for the treatment of breakthrough cancer pain during allergic reactions to chemotherapy infusion

Rev. Soc. Esp. Dolor. 2019; 26(3): 148-153 / DOI: 10.20986/resed.2018.3689/2018

Pulsed radiofrequency treatment in the neuropathy of the pudendal nerve: report of a case

Rev. Soc. Esp. Dolor. 2019; 26(2): 128-129 / DOI: 10.20986/resed.2016.3517/2016

Does pregabalin is a safe drug? Heart failure associated with pregabalin

Rev. Soc. Esp. Dolor. 2019; 26(2): 124-125 / DOI: 10.20986/resed.2017.3537/2016

Myofascial pain syndrome as a cause of postoperative acute pain in hip surgery

Rev. Soc. Esp. Dolor. 2019; 26(2): 117-119 / DOI: 10.20986/resed.2019.3655/2018

Fast opioid detoxification

Rev. Soc. Esp. Dolor. 2019; 26(2): 95-102 / DOI: 10.20986/resed.2019.3681/2018

Influence of psychosocial factors in the experience of musculoskeletal pain: a literatura review

Rev. Soc. Esp. Dolor. 2019; 26(1): 44-51 / DOI: 10.20986/resed.2018.3679/2018

Project adapta: adequacy of treatment in breakthrough cancer pain

Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018

Psychosocial factors in chronic cancer pain: a Delphi study

Rev. Soc. Esp. Dolor. 2019; 26(1): 21-30 / DOI: 10.20986/resed.2018.3658/2018

American Headache Society for the treatment of cluster headache guidelines

Rev. Soc. Esp. Dolor. 2018; 25(6): 362-365 / DOI: 10.20986/resed.2017.3539/2016

Dysphonia as side-effect dose-dependent during treatment with duloxetine

Rev. Soc. Esp. Dolor. 2018; 25(6): 359-359 / DOI: 10.20986/resed.2017.3528/2016

Evidence-based recommendations for the management of neuropathic pain (review of the literature)

Rev. Soc. Esp. Dolor. 2018; 25(6): 349-358 / DOI: 10.20986/resed.2018.3673/2018

Opinaudit study: clinical uses in breakthrough pain, is scientific evidence being followed up?

Rev. Soc. Esp. Dolor. 2018; 25(6): 325-334 / DOI: 10.20986/resed.2018.3634/2017

Use of major opioids for control of pain in hospitalized patients

Rev. Soc. Esp. Dolor. 2018; 25(6): 318-324 / DOI: 10.20986/resed.2018.3629/2017

Proctalgia and pudendal nerve entrapment: an association to know

Rev. Soc. Esp. Dolor. 2018; 25(6): 311-317 / DOI: 10.20986/resed.2018.3623/2017

Radiofrequency thermal and splanchnics nerves block

Rev. Soc. Esp. Dolor. 2018; 25(5): 303-304 / DOI: 10.20986/resed.2016.3509/2016

Implications of bioethics in the treatment of chronic pain: the change of paradigms

Rev. Soc. Esp. Dolor. 2018; 25(5): 291-300 / DOI: 10.20986/resed.2018.3666/2018

Farmacologic adyuvants with saving effect of opioids in the perioperative period

Rev. Soc. Esp. Dolor. 2018; 25(5): 278-290 / DOI: 10.20986/resed.2018.3663/2018

Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report

Rev. Soc. Esp. Dolor. 2018; 25(5): 263-270 / DOI: 10.20986/resed.2017.3625/2017

Pain in the elderly and in patients with cognitive deficit. A DELPHI study

Rev. Soc. Esp. Dolor. 2018; 25(5): 251-262 / DOI: 10.20986/resed.2017.3621/2017

Chrono study: prevalence of breakthrough pain among patients with non-cancer chronic pain in Andalusia, Spain

Rev Soc Esp Dolor 2018; 25(4): 214-221 / DOI: 10.20986/resed.2017.3626/2017

Expenditure, prescription and consumption of analgesic drugs before and during the economic crisis

Rev Soc Esp Dolor 2018; 25(3): 155-162 / DOI: 10.20986/resed.2017.3609/2017

Painometer v2®: a mobile application certified for monitoring patients with pain

Rev Soc Esp Dolor 2018; 25(2):112-120 / DOI: 10.20986/resed.2017.3555/2016

Analgesic efficacy of topical sevoflurane on wounds

Rev Soc Esp Dolor 2018; 25(2): 106-111 / DOI: 10.20986/resed.2017.3617/2017

Potential uses of Mirtazapine in palliative care beyond its antidepressant effect

Rev Soc Esp Dolor 2018; 25(1): 37-44 / DOI: 10.20986/resed.2017.3575/2017

Chronic pain: relationship with prefrontal symptoms and perceived stress

Rev Soc Esp Dolor 2017; 24(4): 179-187 / DOI: 10.20986/resed.2017.3540/2016

The effectiveness of electrical spinal-cord stimulation in type i complex regional pain syndrome. A literature review

Rev Soc Esp Dolor 2017; 24(4): 169-178 / DOI: 10.20986/resed.2016.3501/2016

Control of symptoms in terminally ill patients: effectiveness of opioid treatment for breakthrough dyspnea

Rev Soc Esp Dolor 2017; 24(4): 161-168 / DOI: 10.20986/resed.2017.3582/2017

Paxiflas®: new FDT combination of tramadol/paracetamol for treating moderate to severe pain

Rev Soc Esp Dolor 2017; 24(2):59-67 / DOI: 10.20986/resed.2017.3565/2017

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Instrucciones para citar

Samper D. Intra-articular botulinum toxin and ozone in osteoarthritis. Rev Soc Esp Dolor 2021; 28(13): 73-79 / DOI: 1020986/resed20213857/2020


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 19102 veces.
Este artículo ha sido descargado 10 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 18/01/2021

Publicado: 03/02/2021


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

      Indexada en: